M&A Deal Summary

Bristol-Myers Squibb Acquires Celgene

On January 3, 2019, Bristol-Myers Squibb acquired life science company Celgene for 74.0B USD

Acquisition Highlights
  • This is Bristol-Myers Squibb’s 17th transaction in the Life Science sector.
  • This is Bristol-Myers Squibb’s largest (disclosed) transaction.
  • This is Bristol-Myers Squibb’s 14th transaction in the United States.
  • This is Bristol-Myers Squibb’s 2nd transaction in New Jersey.

M&A Deal Summary
Date 2019-01-03
Target Celgene
Sector Life Science
Buyer(s) Bristol-Myers Squibb
Deal Type Add-on Acquisition
Deal Value 74.0B USD
Advisor(s) J.P. Morgan Securities
Citigroup Investment Banking (Financial)
Wachtell, Lipton, Rosen & Katz (Legal)

Target

Celgene

Summit, New Jersey, United States
website
Celgene Corp. is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene Corp. was established in 1980 and is headquartered in Summit, New Jersey.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bristol-Myers Squibb

New York, New York, United States

website

Category Company
Founded 1887
Sector Life Science
Employees32,200
Revenue 46.2B USD (2022)
DESCRIPTION

Bristol-Myers Squibb is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes. The majority of Bristol-Myers Squibb's revenue comes from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience; and metabolics. Bristol-Myers Squibb was incorporated in 1887 and is based in New York City.

DEAL STATS #
Overall 17 of 23
Sector (Life Science) 17 of 23
Type (Add-on Acquisition) 16 of 21
State (New Jersey) 2 of 2
Country (United States) 14 of 20
Year (2019) 1 of 1
Size (of disclosed) 1 of 19
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-08 Upsa

France

Upsa is a provider of an over-the-counter drugs business. Upsa is based in France.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-06-19 Bristol-Myers Squibb - Anagni Manufacturing Facility

Anagni, Italy

Bristol-Myers Squibb Co. - Anagni Manufacturing Facility is a provider of oral solid, biologics, and sterile product manufacturing and packaging facility.

Sell -
Mergr

Product

Company

Legal